PKD Connection Blog

Go to: PKD Blog
Go to Category: PKD Foundation News, ADPKD, Research

Breaking news: FDA approves first treatment for ADPKD

Today is a historic day in providing hope to patients with polycystic kidney disease. We are excited to announce that the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD).

It is so gratifying to know that, after more than 35 years of research, more than 1,300 research funded projects, over $45M grants awarded, and having leveraged more than $1.5 billion in government funds for PKD research, that progress and hope is real.

Since its founding in 1982, the PKD Foundation’s goal has been to support PKD patients and families from care to cure. We are proud to not only have supported early studies that led to the development of JYNARQUE™ as a treatment, but also helped guide PKD patients to the JYNARQUE™ clinical trials.

Many thanks to the patients who graciously took the time and resources to participate in clinical trials to bring JYNARQUE™ to the PKD community. This treatment would not exist without you.

In other exciting news, this approval from the FDA, along with the essential PKDOC biomarker for TKV established a few years ago, will only help accelerate even more treatments in the coming years. We know of around 20 different biotech and pharma involved in PKD research, along with more clinical trials than ever before in process that the Foundation is actively supporting.

We hope that this is just the beginning of new treatments on the horizon. Our work to provide access to future studies and to new treatments is more energized than ever.

To read our full press release and sign up for JYNARQUE™ updates, please visit pkdcure.org/jynarque. We are also hosting a special webinar about the new treatment with Ron Perrone, M.D., next Monday, April 30. To register, please click here.

 

Leave a Reply

Your email address will not be published. Required fields are marked *